Clinical Trials Directory

Trials / Unknown

UnknownNCT02671123

Does Co-registration of OCT and Angiography Reduce Geographic Miss of Stent Implantation?

Evaluation of Effect of Co-registration Between Optical Coherence Tomography (OCT) and Coronary Angiography Onto OCT Guided Percutaneous Coronary Intervention (PCI)

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
200 (estimated)
Sponsor
St. Francis Hospital, New York · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether co-registration of OCT and angiography reduce geographic miss defined as stent edge dissection or significant residual stenosis at stent edge after stent implantation during percutaneous coronary intervention.

Detailed description

Background: When a stent fails to fully cover the lesion, it is termed "geographic miss" (GM). Optical coherence tomography (OCT) is an intracoronary imaging modality that has higher resolution than conventional intracoronary ultrasound. Although OCT allows identification of the location of the culprit lesion and side branch using automated measures, it is sometimes difficult to identify the exact segment corresponding to angiography. Recently, co-registration of OCT and angiography has become available; however, whether this reduces the incidence of GM during stenting is unknown. Hypothesis: OCT reduces GM during percutaneous coronary intervention. Objectives: 1. Determine the incidence of GM defined as residual disease\* and significant edge dissection† at proximal and distal reference 2. Determine the incidence of stent dislocation (distance between planned and actual stented place) 3. Determine procedural findings (additional stent, total fluoro time, total contrast volume) * Minimum lumen area \<4.0 mm2 in the presence of significant residual plaque within 5 mm distal and proximal to the stent edge. * A flap of vessel wall of \>60° is seen in ≥2 consecutive cross-section image within 5 mm distal and proximal from stent edge Study Design and Methods: Single-center, prospective, randomized study. Consented subjects who are to undergo percutaneous coronary intervention are divided into 2 groups randomly (OCT with co-registration vs OCT without co-registration). After stent deployment guided by OCT, dissection, residual disease at the stent edge, and distance between planned and actual stent location are assessed using OCT or angiography. Additional stent deployment, procedure time, total fluoroscopy time, and total contrast volume are also evaluated. Sample size considerations: OCT with co-registration: 100, OCT without co-registration: 100 (α=0.05, β =0.2). In a retrospective evaluation, the incidence of residual disease (lumen area \<4.0 mm2 in the presence of significant residual plaque) or significant stent edge dissection was 36% (18/50, 34% \[17/50\] with residual stenosis, 4% \[2/50\] with significant edge dissection). Under the assumption that GM occurs in 36% of patients without co-registration and 18% of patients with co-registration, a group of 190 patients yields a power 80% (with a 2-sided α=0.05) to detect a difference in GM between patients with and without co-registration. In order to account for patient drop out and non-evaluable OCT recordings (5%), a total of 200 patients will be enrolled.

Conditions

Interventions

TypeNameDescription
PROCEDURECoronary PCI with OCT with Co RegistrationCo-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.
PROCEDURECoronary PCI with OCT without Co RegistrationCoronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.

Timeline

Start date
2016-02-01
Primary completion
2016-12-01
Completion
2016-12-01
First posted
2016-02-02
Last updated
2016-02-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02671123. Inclusion in this directory is not an endorsement.